Pipeline & Regulatory Roadmap
Two preclinical programs. PTSD first.
Xycota is advancing two central nervous system (CNS) candidates: XYCO-02, a sub-perceptual oral psilocybin capsule designed for a proposed at-home study in mild PTSD, and XYCO-01, a preclinical exosome-encapsulated psilocin candidate for frontotemporal dementia (FTD). Both programs are preclinical and investigational.
Two-program comparison
| Candidate | Delivery | Indication | Current Stage | Next Milestone | What That Milestone Would Establish |
|---|---|---|---|---|---|
|
XYCO-02
Lead candidate
|
Sub-perceptual oral psilocybin capsule
Proposed 28-day at-home dosing
|
Mild PTSD |
Preclinical
Health Canada CTA in preparation with KGK Science
|
Complete Canadian Clinical Trial Application and submit with KGK Science | Whether Health Canada authorizes the proposed 28-day at-home mild PTSD study and accepts the third-party low-dose precedent for a Phase 1 PK/PD waiver |
|
XYCO-01
Follow-on candidate
|
Exosome-encapsulated psilocin
Cell-derived nano-vesicle BBB vector
|
Frontotemporal dementia (FTD) |
Preclinical
FDA Orphan Drug Designation (ODD) application filed
|
Head-to-head preclinical FTD animal study (gated behind XYCO-02 initiation) | Whether exosome-encapsulated psilocin improves brain biodistribution and FTD pathology markers compared with free psilocin and empty exosomes in an FDA-aligned animal model |
Program 01 · Lead Candidate · Planned Clinical Study
XYCO-02 (sub-perceptual oral psilocybin capsule)
The lead program: a standardized, sub-perceptual oral capsule proposed for a 28-day at-home study in adults with mild PTSD, at a dose formulated to minimize noticeable psychedelic effects.
01 · Proposed Dosing & Control
28-Day Outpatient Regimen
Randomized, double-blind, placebo-controlled 28-day at-home study comparing a standardized, sub-perceptual oral psilocybin capsule against matched placebo in adults with mild PTSD.
02 · Planned Readouts
CAPS-5 + Blood BDNF
Primary clinical endpoint: CAPS-5 symptom score. Planned blood biomarker: serum BDNF measured alongside CAPS-5. A change in blood BDNF alone would not establish brain repair or receptor engagement.
03 · Open Blinding Question
Repeated-Dose Blinding
Single-dose research in healthy adults has evaluated low-dose oral psilocybin to characterize perceptual thresholds relative to placebo (Levy-Cooperman et al., 2026). Whether blinding holds during repeated sub-perceptual dosing in mild PTSD remains unknown.
Indication & Proposed Delivery
Mild Post-Traumatic Stress Disorder (mild PTSD) · Standardized sub-perceptual oral psilocybin capsule proposed for a 28-day at-home study design.
Regulatory Jurisdiction & CRO Partner
Health Canada Clinical Trial Application (CTA) framework · Contract Research Organization (CRO) partner KGK Science (London, Ontario).
Scientific Rationale & Mechanism Hypothesis
What the study is designed to test: whether repeated low-dose psilocybin can support symptom improvement in mild PTSD while minimizing noticeable psychedelic effects.
In a 2026 Fragile X rat study (Ascone F, Buzzelli V, Mottarlini F, et al. Neuropsychopharmacology 2026; DOI: 10.1038/s41386-026-02361-x), repeated low doses of oral psilocybin improved object-recognition memory through a TrkB-dependent mechanism that remained when 5-HT2A was blocked. Whether this mechanism translates to people with mild PTSD has not yet been tested.
Proposed Study Design & Readouts
- Primary Clinical Endpoint (CAPS-5): Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) symptom scores in a proposed randomized, double-blind, placebo-controlled 28-day study.
- Planned Blood Biomarker (Serum BDNF): Researchers plan to measure BDNF levels in blood alongside CAPS-5 symptom scores. A change in blood BDNF would not by itself establish repair or receptor engagement in the brain.
- Blinding Question: Blinded single-dose research in healthy adults has evaluated low-dose oral psilocybin to characterize perceptual thresholds relative to placebo (Levy-Cooperman et al., 2026). Whether participants with mild PTSD can distinguish XYCO-02 from placebo during repeated dosing remains an open question.
XYCO-02 Regulatory Context & History
Regulatory context: what we have and what we do not
Our CRO partner KGK Science previously ran a Health Canada authorized study of low-dose, sub-perceptual oral psilocybin in adults with Fragile X Syndrome (NCT05832255), sponsored by Nova Mentis Life Science Corp. That study was open-label, single-arm, enrolled up to 10 participants, and is currently listed as suspended pending protocol revisions. Xycota does not own or control that dataset.
What it gives us is narrower than a dataset: the same CRO, prior cGMP low-dose capsule experience, and an existing Health Canada authorization precedent for sub-perceptual psilocybin dosing in an outpatient setting. Whether that supports a Phase 1 PK/PD waiver for XYCO-02 is a question for Health Canada, and we have not yet entered formal dialogue with the regulator.
Controlled substance logistics: Psilocybin and psilocin are Schedule I controlled substances in the United States under the Controlled Substances Act and controlled substances in Canada under the Controlled Drugs and Substances Act. Research handling, current Good Manufacturing Practice (cGMP) manufacturing, import/export, and clinical distribution require DEA Schedule I researcher/manufacturer registrations in the US and a Health Canada Controlled Substances Dealer's License in Canada. Xycota does not directly handle bulk Schedule I material; all formulation, analytical testing, storage, and trial supply logistics are planned to run through licensed contract partners, including KGK Science in Canada.
XYCO-02 Milestone Sequence
Preclinical Rat Mechanism Paper
Ascone et al., Neuropsychopharmacology (2026), DOI: 10.1038/s41386-026-02361-x.
Health Canada CTA & Waiver Request
Complete Canadian Clinical Trial Application and submit with KGK Science (30-day statutory review window following submission).
28-Day Mild PTSD Study Initiation
Subject to Health Canada CTA authorization, ethics approval, and financing; measures CAPS-5 and blood BDNF.
Program 02 · Follow-On Neurodegenerative Candidate
XYCO-01 (exosome-encapsulated psilocin)
The second program targets frontotemporal dementia (FTD), a rare, fatal form of early-onset dementia with no approved disease-modifying treatment.
Indication & Proposed Delivery
Frontotemporal Dementia (FTD) and related tauopathy · Psilocin engineered into native, cell-derived exosomes.
Regulatory Jurisdiction
U.S. Food and Drug Administration (FDA Office of Orphan Products Development / CDER).
Scientific Rationale & Mechanism Hypothesis
What the candidate is designed to test: whether cell-derived exosomes can carry psilocin across the blood-brain barrier to engage BDNF/TrkB signaling in frontotemporal cortical tissue.
Because the blood-brain barrier excludes over 98% of small-molecule drugs (Pardridge, 2005), XYCO-01 is designed to encapsulate psilocin inside native extracellular vesicles. Its effects on brain biodistribution, tau/TDP-43 pathology, and neuroinflammation are hypotheses to be tested in preclinical animal studies.
XYCO-01 Regulatory Context & Gating
FDA Orphan Drug Designation filing and head-to-head animal controls
- FDA Orphan Drug Designation (ODD) application filed: FTD affects fewer than 200,000 people in the United States. If granted by the FDA, Orphan Drug Designation provides incentives including potential 7-year U.S. market exclusivity upon marketing approval, qualified clinical trial tax credits, and a PDUFA application fee waiver.
- FDA-aligned head-to-head control design: In alignment with FDA feedback following the ODD application, Xycota's planned preclinical validation study is designed to evaluate exosome-encapsulated psilocin head-to-head against free unencapsulated psilocin and empty-exosome controls in an FTD-relevant animal model (such as PS19 MAPT tauopathy or TARDBP TDP-43 pathology) to be selected with FDA input.
- Capital discipline: Execution of the XYCO-01 animal efficacy study is gated behind the clinical initiation of XYCO-02 to preserve capital efficiency.
XYCO-01 Milestone Sequence
FDA ODD Application Submitted
Orphan Drug Designation application filed with the U.S. FDA Office of Orphan Products Development for FTD.
Head-to-Head FTD Animal Study
Evaluate exosome-encapsulated psilocin vs. free psilocin and empty exosomes in an FDA-aligned FTD animal model.
Supplemental ODD Data Submission
Submit preclinical CNS biodistribution and efficacy package to FDA OOPD.